A metabolic hypothesis is presented for insulin resistance in obesity, in the presence or absence of Type 2 (noninsulin-dependent) diabetes mellitus. It is based on physiological mechanisms including a series of negative feed-back mechanisms, with the inhibition of the function of the glycogen cycle in skeletal muscle as a consequence of decreased glucose utilization resulting from increased lipid oxidation in the obese. It considers the inhibition of glycogen synthase activity together with inhibition of glucose storage and irapaired glucose tolerance. The prolonged duration of increased lipid oxidation, considered as the initial cause, may lead to Type 2 diabetes. This hypothesis is compatible with others based on the inhibition of insulin receptor kinase and of glucose transporter activities.
Insulin resistance is seen early in the development of obesity and results in an impairment of glucose metabolism which may lead to Type 2 (non-insulin-dependent) diabetes mellitus. This has been documented using a variety of experimental techniques. The term "insulin resistance" was initially applied to patients who needed larger amounts of insulin than expected to control their hyperglycaemia. In 1939, Himsworth described "an insulin-insensitive type which predominates in the older age-group and may be preceded by obesity" different from the insulin-sensitive type of diabetes [1] . Since 1960 the development of assays to measure plasma insulin have extended the term to include situations where hyperglycaemia is present despite normal or high circulating plasma insulin concentrations. This often occurs in adultonset diabetes, especially when accompanied by obesity. Insulin resistance may result from a resistance to glucose utilization in the presence of a normally secreting pancreas as well as from defects in insulin action. Muscle plays a major role in glucose disposal, both in glucose oxidation and storage. Most ingested or infused glucose enters the muscles [2, 3] where it is stored as glycogen [4] . A defect in glycogen synthesis has been observed in Type 2 diabetic patients [5] , indicating that impairment of glucose storage in muscles plays an important role in the hyperglycaemia of Type 2 diabetes.
In contrast to the glucose stored in the liver, which can be released into the systemic circulation, glucose cannot be released as such in the muscle. It can only be oxidized in situ, or released as lactate or alanine. As the maximal glycogen concentration is limited in muscle [6] , a defect in the oxidation of glucose from the glycogen stores in the muscles might limit the possibilities for further glucose storage, resulting in glucose intolerance. This situation is seen in obesity, where the characteristic increase in lipid oxidation, is reflected by a decrease in glucose oxidation [7] .
The purpose of this report is to examine how the metabolic changes resulting from obesity with or without diabetes may affect insulin resistance. A metabolic hypothesis for insulin resistance is proposed, which is compatible with the known inhibition of both insulin receptor tyrosine kinase and insulin-regulatable glucose transporter activities in human skeletal muscle.
I. Regulation of muscle glycogen synthesis and breakdown
Both glycogen synthesis and breakdown are regulated by a double regulatory mechanism. The activity of glycogen synthase, the enzyme which catalyses glycogen synthesis, is stimulated by glucose 6-phosphate, an allosteric activator of glycogen synthase b, the inactive form of the enzyme [8] and by insulin (Fig. 1) . Conversely, glycogen synthase activity is inhibited by increased glycogen concentration [9, 10] . Activation of glycogen synthase is due /; (':)~ Glycogen cAMP-depend. Glycogen (gg/mg protein) (preclamp) Fig.3 . Correlations between muscle glycogen synthase activity at the end of the glucose-insulin infusion (clamp) and muscle glycogen concentration at the end of the [ntralipid infusion preceding the glucose-insulin infusion in muscle biopsies, after mathematical transformation into a rectangular hyperbola. From R. Munger et al. [30] (with permission) to a dephosphorylation by protein phosphatases [11] , while different protein kinases, acting at different phosphorylation sites, cause inactivation of the enzyme [12] . In contrast, glycogen phosphorylase, the enzyme which catalyses glycogen breakdown, is inhibited by a rise in intracellular glucose or glucose 6-phosphate [13] and by insulin, and is stimulated by an increase in glycogen concentration [14] . The phosphorylation of glycogen phosphorylase by several phosphorylase kinases catalyses its activation while dephosphorylation by phosphatases inhibits it activity [12] . Both glycogen synthase and phosphorylase, which have opposite effects on glycogen metabolism, are controlled by a double regulatory system, i. e. levels of glucose 6-phosphate and insulin stimulate synthase and inhibit phosphorylase activity, thus favouring glycogen synthesis, and the intracellular glycogen concentration which inhibits synthase and stimulates phosphorylase activity, thus favouring its own breakdown and utilization.
Since the glycogen stores have a limited capacity [6] , a decrease in the oxidation of glycogen might affect new glycogen synthesis by a negative feed-back mechanism of glycogen concentration on synthase activity [9, 10] . This feed-back mechanism might, therefore, play an important role in the regulation of glycogen synthesis in the conditions of decreased glucose oxidation, which occur in obesity with or without diabetes.
Effects of lipids on glycogen synthesis
The inhibitory effect of increased lipid oxidation on glucose oxidation in muscle was reported by Randle et al. in 1963 [15] . Infusions of triglyceride emulsions (Intralipid, Vitrum, Stockholm, Sweden) have confirmed this inhibitory effect on glucose oxidation in man [16, 17] and, also, on glucose storage [18] [19] [20] [21] [22] [23] . Fat infusions have therefore been used as a model for the increased lipid oxidation which is characteristic of obesity [24] .
In contrast to glucose oxidation which is directly inhibited by a rise in lipid oxidation, changes in glucose storage are only indirectly related to changes in lipid oxidation. Inhibition of glucose storage occurs as a late consequence of the metabolic changes induced by increased lipid oxidation [21, 22] . The study of Boden et al.
[23] confirmed the delayed effect of lipid infusion on the inhibition of glucose storage together with the inhibition of glycogen synthase activity, compared to the rapid effect of Intralipid simultaneously raising lipid oxidation and lowering glucose oxidation.
A close relationship exists between glucose storage and glycogen synthase activity [25] [26] [27] . In particular the decrease in synthase activity when glucose storage or uptake is decreased [25] [26] [27] [28] [29] proves the importance of glycogen synthase activity in controlling glucose storage. Glycogen synthase activity was found to be decreased in obesity [26, 27] and Type 2 diabetes [28, 29] .
The increase in lipid oxidation, which is generally observed in obesity [7, 24] has an inhibitory effect on glucose oxidation, as demonstrated during euglycaemic hyperinsulinaemic clamp studies [24] . Therefore it can be expected that this inhibitory effect will affect intramuscular glycogen concentration by decreasing or even blocking glycogen breakdown in basal conditions. This will trigger the negative feed-back mechanism of glycogen concentration on glycogen synthase activity. This sequence of events has been studied by Munger et al. [30] . In their study, performed under continuous indirect calorimetry, a 2-h Intralipid infusion was carried out in a group of normal subjects in the post-absorptive state to raise lipid oxidation. It was immediately followed by a 2-h euglycaemic hyperinsufinaemic clamp to measure glucose uptake and storage. A positive correlation was demonstrated between the changes in glycogen concentration in the muscle biopsies and the changes in lipid oxidation measured by means of indirect calorimetry (Fig. 2) . Simultaneously the changes in glucose oxidation correlated with glycogen concentration changes inversely.
Following the Intralipid infusion, insulin-stimulated glycogen synthase activities measured in muscle biopsies taken after the clamp correlated inversely with muscle glycogen concentrations before the clamp (Fig.3) . The correlation presented the typical shape of an enzyme in- Glycogen (~g/mg protein)
Max specific activity hibition curve as a function of the product (glycogen) concentration. It showed that the changes in the individual values of insulin-stimulated synthase activity were negatively related to those of the glycogen concentration preceding the glucose-insulin infusion. It corresponded to the known inhibition of glycogen synthase activity by increasing intracellular glycogen concentrations [9, 10] . The delayed effect of the Intralipid infusion on the activity of glycogen synthase suggests that changes in synthase activity are not a direct consequence of the rise in non-esterifled fatty acids (NEFA) but result from the metabolic changes produced by the fat infusion. This supports the conclusions of Bonadonna et al. Left: after a glucose load, the rise in plasma glucose and insulin concentrations is followed by a rise in glucose 6-phosphate (G-6-P) and glucose 1-phosphate (G-l-P) which stimulates glycogen synthase activity and consequently glycogen synthesis, while inhibiting glycogen phosphorylase activity. Right: after the return of glycaemia to basal levels, the inhibition of glycogen phosphorylase activity by the increased concentration of G-6-P is discontinued while, on the contrary, the high intracellular glycogen concentration stimulates this enzymatic activity. This stimulates glycogen breakdown and the mobilization of glucose for oxidative purposes. Simultaneously the increased glycogen concentration might inhibit glycogen synthase activity. OGTT, Oral glucose tolerance test Glucose storage rate in non-diabetic obese subjects (left) and diabetic obese subjects (right) during euglycaemic clamps and oral glucose tolerance tests (OGTT). Note the marked impairment in glucose storage in the two non-diabetic obese groups (with normal glucose tolerance (NGT) and impaired glucose tolerance (IGT)) during the clamps and the absence of any change in glucose storage during the OGTT. During OGTT, however, glucose storage occurs at higher glycaemia (obese subjects with IGT) and higher insulinaemia (obese subjects with NGT and IGT). In contrast, glucose storage in obese diabetic subjects is decreased both during the clamp and the OGTT in the two diabetic obese groups. Based on data from J. R Felber et al. [35] (with permission) tween the two treatments (modifications of plasma NEFA or glucose concentrations) on insulin-mediated glucose disposal, in particular glucose storage. This is consistent with the hypothesis of two separate metabolic pathways regulating glycogen synthase activity, i.e. one path being the effect of glucose and insulin and the other, the effect of glycogen concentration which is influenced by NEFA availability. While glycogen synthase stimulates glycogen synthesis during the rise in glycaemia which follows carbohydrate absorption, phosphorylase catalyses glycogenolysis when glucose from the glycogen stores is needed for energy expenditure in muscles between meals. Munger et al. [30] reported a strong positive correlation between glycogen phosphorylase activity and glycogen concentration in muscle biopsies at the end of the Intralipid infusion, which presented the typical shape of an enzyme stimulation curve as a function of the substrate (glycogen) concentration (Fig.5) . Even though the experimental conditions were not those of an enzymatic assay, this significant correlation shows that the changes in the individual values of phosphorylase activity are related to those of the glycogen concentration. This correlation was observed only after the 2-h Intralipid infusion, suggesting that it is a consequence of the inhibition of glycogen breakdown consecutive to the increase in lipid oxidation.
Thus, these data are compatible with a mechanism by which glycogen, when in excess, inhibits its own synthesis and stimulates its degradation through the mobilization of glucose from the glycogen stores. The inhibition of glycogen synthase activity and the stimulation of glycogen phosphorylase activity are probably progressive and start as soon as glycogen concentration rises above a certain threshold. 
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I~g.8. Regulation of glycogen synthesis and breakdown in Type 2 diabetes. The absence of return of glycaemia to basal levels as seen in Type 2 diabetes prevents the breakdown of glycogen for oxidative purposes. The high glucose 6-phosphate (G-6-P) and glucose 1-phosphate (G-l-P) concentrations, maintained by the high plasma glucose levels, cause the inhibition of glycogen phosphorylase activity while the high glycogen concentrations resulting from the absence of glycogen breakdown inhibit glycogen synthase activity and consequently further glycogen synthesis. These inhibitions remain unchanged following a glucose load, which only aggravates the situation, and the two schemes are identical. As a consequence of the important reduction in the activity of the glycogen cycle, glucose oxidation originates essentially from exogenous glucose, i.e. from the high circulating glucose concentrations. OGTT, Oral glucose tolerance test
II. Regulation of muscle glycogen synthesis and breakdown in pathophysiology
Glycogen synthesis is the major mechanism for glucose disposal after a glucose load in the resting state [2, 4, 32] . It allows a large fraction of glucose to leave the glucose space for storage in the tissues, mainly in muscle [2] [3] [4] . In normal subjects, the acute rise in intracellular glucose 6-phosphate after a carbohydrate-containing meal or a glucose load, together with the action of insulin, stimulates glycogen synthase activity, thus promoting glycogen synthesis (Fig. 6 ). This mechanism occurs rapidly, allowing plasma glucose to return to its basal level after a brief rise in glycaemia. The stimulatory action of glucose 6-phosphate on glycogen synthase activity occurs simultaneously with the inhibition of glycogen phosphorylase activity. This first phase corresponds to the duration of the rise in glycaemia and in insulinaemia above basal levels. When glycaemia has returned to basal level, the lowering of intracellular glucose and glucose 6-phosphate concentrations removes the inhibition on glycogen phosphorylase activity, which allows glycogen breakdown to occur. Muscle glycogen can then be utilized in situ by providing glucose as a substrate for energy expenditure, mainly in resting postural muscles and during exercise. Approximately 20 % of hepatic glucose production is taken up by the muscles in the basal state after an overnight fast [33] . Glucose is not only being oxidized, but a certain amount of glycogen is being synthesized and stored in the resting state [34] .
Alternating between glycogen synthesis and breakdown in muscles represents an important physiological phenomenon which allows glucose to be stored and utilized according to the energy needs. When this alternance cannot occur, the function of the glycogen cycle becomes impaired. If the glucose resulting from glycogen breakdown is not utilized, this may block this alternating cycle and, consequently, prevent further glycogen synthesis: thus the glycogen cycle may be impaired.
Insulin resistance in non-diabetic obesity
It appears, from the different observations reported above, that impairment in the utilization of the glycogen stores might affect the regulation of glycogen synthesis and breakdown. Increased availability of NEFA may, therefore, slow down the function of the glycogen cycle by decreasing the oxidation of glucose from the glycogen stores. The resulting lack of utilization of glycogen would cause, in turn, inhibition of glycogen synthase activity and, therefore, of glucose storage. This situation is likely to occur in obesity where lipid oxidation is generally increased [7, 24] . The use of the euglycaemic hyperinsulinaemic clamp technique associated with indirect calorimetry reveals an impairment in glucose storage, demonstrating insulin resistance even in non-diabetic obese subjects (Fig. 7) . When glucose is given orally to non-diabetic obese subjects, the impairment of glucose storage is, however, compensated in the obese subjects by a rise in glycaemia and insulinaemia which cancels the impairment of glucose uptake and storage induced by the excess fatty acid concentration [35] . Thus, the non-diabetic obese subject is in a compensated state.
Insulin resistance in obese patients with Type 2 diabetes
With the aggravation of impaired glucose tolerance, the return of plasma glucose to basal levels does not occur, even after an overnight fast, resulting in diabetes (Fig. 8) . The compensatory effects of the hyperglycaemic and hyperinsulinaemic responses to a glucose load are unable to overcome the resistance to glucose disposal (Fig.7) . In contrast to non-diabetic obesity, glucose storage is decreased not only during the normoglycaemic conditions of the euglycaemic hyperinsulinaemic clamp, but also during an oral glucose tolerance test (OGTT), where the rises in glycaemia and insulinaemia do not overcome the resistance to glucose storage and do not compensate for this resistance. The major defect in diabetes resides in the decrease in the storage of glucose as glycogen [5, 35] . The studies on the evolution from obesity to diabetes show the progressive prolongation of the period of hyperglycaemia preceding the return to basal levels, after a glucose load or a carbohydrate-containing meal which in time, will lead to a rise in the fasting plasma glucose concentration [36] . The non-return to normal fasting glycaemia indicates that glucose of either endogenous or exogenous origin, has not been entirely taken up by muscles. In a study of 67 obese subjects grouped according to their duration of obesity [37] none of them had an increase in fasting glycaemia for the first 17 years of obesity duration (Fig. 9) . Thereafter, a large proportion of the patients showed elevated values of fasting glycaemia.
None of the subjects had an impairment of the rate of glucose storage during a 100-g OGTT taken during the first 17 years of obesity duration. But, a large proportion of the patients developed a decrease in the rate of glucose storage. The patients with decreased glucose storage capacity were those who had presented increased basal glycaemia. A negative correlation was shown between the rate of glucose storage and fasting glucose concentration [37] . This negative correlation suggests that, when fasting hyperglycaemia occurs, i.e. when glycaemia has not returned to its basal level, exogenous glucose cannot be stored normally. The breaking point, which occurs between the compensated state with normal basal glycaemia and normal rate of glucose storage, and the decompensated state with elevated basal glycaemia and decreased glucose storage, corresponds to the occurrence of diabetes (Fig. 9) . This breaking point takes place in the continuum which exists in the development of diabetes in obesity; there is a progressive aggravation from obesity with normal glucose tolerance to obesity with impaired glucose tolerance, hyperinsulinaemic and finally hypoinsulinaemic diabetes. This continuum has been confirmed by longitudinal studies [36, 38, 39] .
In diabetes, after an overnight fast glycaemia does not return to normal basal fasting levels which inhibits glycogen mobilization through the inhibitory effect of intracellular glucose and glucose 6-phosphate concentrations on glycogen phosphorylase [13] (Fig.8) . This, in turn, maintains the inhibitory effect of an increased intracellular glycogen concentration on glycogen synthase activity. Glycogen cycling is slowed down, thus preventing or reducing glycogen synthesis after glucose intake. Free intracellular glucose and glucose 6-phosphate were shown to increase in muscle during prolonged hyperglycaemia, as demonstrated by Richter et al. [40] in studies using rat hindquarter muscle preparations. Increase in muscle glu~ cose 6-phosphate concentration was also recently reported by Ortmeyer et al. [41] in prediabetic obese and diabetic Rhesus monkeys under insulin stimulated conditions, together with a negative correlation with glycogen synthase activity. Inhibition of glycogen phosphorylase activity by free glucose and glucose 6-phosphate resulting in a decrease in glycogen turnover is probably the mechanism by which chronic hyperglycaemia causes inhibition of glycogen synthase activity [26] and, consequently, of intracellular glucose disposal and of glucose transport [40] . This mechanism might contribute to the well-established entity of glucose toxicity, together with the progressive impairment of insulin secretion [42] .
An elevated glucose storage in the basal state together with a decrease in glycogen synthase activity and in glucose storage following a glucose load were recently reported by Schalin-Jfintti et al. [34] in Type 2 diabetic subjects. It shows a marked decrease in the alternance in glucose storage between the basal and the insulin-stimulated state. Lack of glycogen synthase activity and a decrease in glucose storage is generally observed in Type 2 diabetes [28, 29] . As seen above (Fig. 9) , impaired glucose storage occurs in patients whose fasting plasma glucose concentrations are chronically increased.
In contrast to acute hyperglycaemia, which stimulates glycogen synthase activity [8] , chronic hypergtycaemia causes inhibition of glycogen synthase activity. This probably occurs by preventing the utilization of glucose from the glycogen stores by the same glycogen-sparing mech- anism as the one which is caused by the preferential use of NEFA. In acute hyperglycaemia, the simultaneous stimulation of glycogen synthase activity and inhibition of glycogen phosphorylase activity leads to muscle glycogen accumulation. Later, when glycaemia has returned to normal basal values, the breakdown of glycogen stores occurs together with the removal of the inhibition of glycogen phosphorylase activity (Fig.6 ). By contrast, chronic hyperglycaemia, by suppressing the physiological alternance of high and low plasma glucose concentrations, chronically maintains the inhibition of glycogen phosphorylase activity by glucose 6-phosphate, thus blocking the cyclic function of the glycogen cycle, and therefore the capacity for glycogen synthesis (Fig. 8) . Impairment of the function of the glycogen cycle can be considered as a major cause of insulin resistance. A lack of glucose storage results in a rise in glycaemia in the presence of a parallel increase in insulin concentration, a situation which is typical of insulin resistance. This is illustrated by a study of a group of obese diabetic patients with increased insulin response to a 100-g oral glucose load [43] . The lowering of basal glycaemia following a 3-day protein-supplemented fast resulted in a marked increase in the rate of glucose storage, from 26 to 52 g/3 h (or 0.8 to 1.6 mmol/min) (Fig. 10) . This shows the importance of a decrease in glucose concentration to favour glycogen mobilization and to allow the functioning of the glycogen cycle through the necessary alternance of glycogen synthesis and breakdown. In this study, glucose storage was significantly impaired before the 3-day fast while glucose oxidation had remained within physiological rates, probably as a consequence of the increased glycaemia. After the 3-day fast, glucose storage had returned to near-normal values while glucose oxidation was markedly decreased as a consequence of the rise in plasma NEFA following the fast. This dissociation between glucose oxidation and storage suggests that the primary phenomenon of insulin resistance is not found in the early part of the metabolic pathway which leads from insulin receptor to glucose metabolism, but in glucose metabolism itself (Fig. 1) . In contrast, if a defect was present at an early location (insulin receptor, glucose transport systems), this would cause a parallel defect in glucose oxidation and storage. These results favour the hypothesis of insulin resistance being a consequence of excess substrates (glucose and NEFA) inhibiting glycogen turnover, and not primarily a defect of insulin receptor or of glucose transport systems.
Discussion
The metabolic hypothesis of insulin resistance in obesity with or without diabetes presented here is compatible with other hypotheses, especially those of a decrease in insulin-receptor kinase activity and of a decrease in insulinstimulatable glucose transporter activity.
Decreased binding and tyrosine kinase activity of muscle insulin receptor has been reported in obesity and Type 2 diabetes by several authors [44] [45] [46] . However, these changes were not accompanied by changes in the number of insulin receptors [44] or in the structural characteristics of the receptors [45] . Similarly the decrease in glucose transport observed in muscle-strip preparations of Type 2 diabetic patients [47] is not accompanied by changes in GLUT4 content in obese or Type 2 diabetic subjects [48] [49] [50] . GLUT4 gene expression was shown to be normal in skeletal muscle from patients with Type 2 diabetes [50] .
These observations suggest a functional origin for the changes observed in the activity of the insulin receptor and the glucose transporters. Downregulation of glucose transport by prolonged hyperglycaemia [51] suggests a mechanism by which the increased intracellular glucose concentration consecutive to the inhibition of glycogen synthase activity could inhibit glucose transport and insulin receptor activities by a feed-back mechanism. The decreased function of the glycogen cycle would cause the inhibition not only of glycogen synthase activity, but extend to the preceding steps of glucose transport and insulin binding.
It is important to realize that the metabolic changes observed in obesity, in the absence as well as in the presence of diabetes, are dependent upon physiological mechanisms. This is supported by the partial reversibility of the metabolic alterations. Golay et al. [52, 53] have studied the effects of weight loss on lipid and glucose metabolism. They have shown in obese subjects initially presenting with impaired glucose tolerance, that a weight loss of 10 kg or more was followed by a decrease in lipid oxidation to normal rates together with an increase in glucose oxidation; in addition, the glucose and insulin responses to the oral glucose load were normalized.
Type 2 diabetes is a multifactorial syndrome which involves betacell, muscle and liver functions [54] . In obesity and Type 2 diabetes, longitudinal observations show that an impaired ability of the pancreas to compensate for the increasing resistance to glucose storage and oxidation may certainly play an additional role in the development of diabetes in these subjects. Impaired suppression of hepatic glucose production is another factor which contributes to insulin resistance, together with an increase in glucose cycling in the later stages of Type 2 diabetes [55] . The genetic component of insulin resistance in obesity and Type 2 diabetes may consist of the limited capacity to react to the chronic changes induced by a permanent increase in lipid oxidation.
In conclusion, a metabolic hypothesis is presented for insulin resistance in obesity. It is based on a series of negative feed-back mechanisms with the inhibition of the function of the glycogen cycle, a consequence of decreased glycogen utilization. It considers the inhibition of glycogen synthase activity together with inhibition of glucose storage and impaired glucose tolerance. With time, the initial cause (increased lipid oxidation) may lead to Type 2 diabetes. This hypothesis does not exclude other mechanisms based on the inhibition of the insulin receptor and the glucose transporter activities, but these alterations should be considered as consequences, rather than causes, of the impairment of the glycogen cycle. The concept of "insulin resistance" could be replaced by the concept of "substrate competition" which leads to limited glucose uptake and storage in the presence of a chronic excess of NEFA. As a consequence of this substrate competition, insulin is less effective in its role of regulating glucose homeostasis, and a state of "insulin resistance" is created.
